|
CA2640476A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Eli Lilly And Company |
Compounds and methods for modulating fx-receptors
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
KR101175859B1
(ko)
|
2007-12-04 |
2012-08-24 |
에프. 호프만-라 로슈 아게 |
이속사졸로-피라진 유도체
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
CA2744817C
(en)
*
|
2008-11-26 |
2020-07-07 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US8222246B2
(en)
|
2009-04-02 |
2012-07-17 |
Hoffmann-La Roche Inc. |
Substituted isoxazoles
|
|
US20100280019A1
(en)
|
2009-04-30 |
2010-11-04 |
Roland Jakob-Roetne |
Isoxazoles
|
|
JP5460858B2
(ja)
|
2009-05-05 |
2014-04-02 |
エフ．ホフマン−ラ ロシュ アーゲー |
イソオキサゾール−ピラゾール誘導体
|
|
CA2759598C
(en)
|
2009-05-05 |
2017-09-12 |
F. Hoffmann-La Roche Ag |
Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
|
|
KR101367012B1
(ko)
|
2009-05-05 |
2014-03-14 |
에프. 호프만-라 로슈 아게 |
이속사졸-피리딘 유도체
|
|
CA2760597C
(en)
|
2009-05-05 |
2017-08-22 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyridazine derivatives
|
|
BRPI1013766A2
(pt)
|
2009-05-07 |
2016-04-05 |
Hoffmann La Roche |
"derivados de isoxazol-piridina como moduladores de gaba"
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
EP2575821B1
(en)
|
2010-05-26 |
2015-08-12 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
CA2852957C
(en)
|
2011-10-28 |
2020-08-04 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
|
|
CN104023727B
(zh)
|
2011-10-28 |
2017-04-05 |
鲁美纳医药公司 |
用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
|
|
US20140275090A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
CN105228615A
(zh)
|
2013-03-15 |
2016-01-06 |
鲁美纳医药公司 |
用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
|
|
DK3043865T3
(da)
|
2013-09-11 |
2021-02-01 |
Univ Claude Bernard Lyon |
Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
|
|
KR102515248B1
(ko)
|
2013-11-22 |
2023-03-29 |
사브레 테라퓨틱스 엘엘씨 |
오토탁신 억제제 화합물
|
|
CN104045635A
(zh)
*
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
US10894054B2
(en)
|
2015-04-07 |
2021-01-19 |
Intercept Pharmaceuticals, Inc. |
FXR agonist compositions for combination therapy
|
|
MX2017015225A
(es)
*
|
2015-05-27 |
2018-02-19 |
Pharmakea Inc |
Inhibidores de la autotaxina y sus usos.
|
|
WO2017133521A1
(zh)
*
|
2016-02-01 |
2017-08-10 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017189663A1
(en)
*
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
WO2017201152A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201150A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
BR112018073460A2
(pt)
*
|
2016-05-25 |
2019-07-09 |
Akarna Therapeutics Ltd |
terapias combinadas usando moduladores do receptor farnesoide x (fxr)
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
|
|
MX385718B
(es)
|
2016-06-13 |
2025-03-18 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4).
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
US10450306B2
(en)
|
2016-10-04 |
2019-10-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
PT3600309T
(pt)
|
2017-03-28 |
2022-10-03 |
Gilead Sciences Inc |
Combinações terapêuticas para o tratamento de doenças hepáticas
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
PL3612520T3
(pl)
|
2017-04-12 |
2022-03-21 |
Il Dong Pharmaceutical Co., Ltd. |
Pochodne izoksazolu jako agoniści receptora jądrowego i ich zastosowania
|
|
PE20201170A1
(es)
|
2017-11-01 |
2020-10-28 |
Bristol Myers Squibb Co |
Compuestos biciclicos en puente como moduladores del receptor farnesoide x
|
|
AU2018360575A1
(en)
*
|
2017-11-01 |
2020-06-18 |
Bristol-Myers Squibb Company |
Alkene spirocyclic compounds as farnesoid X receptor modulators
|
|
KR102731924B1
(ko)
|
2017-11-01 |
2024-11-19 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
|
|
CN111278817B
(zh)
|
2017-11-01 |
2023-05-16 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的多环化合物
|
|
CN111511731B
(zh)
|
2017-11-01 |
2023-05-23 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的烯烃化合物
|
|
WO2019118571A1
(en)
|
2017-12-12 |
2019-06-20 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
US10829486B2
(en)
|
2018-02-14 |
2020-11-10 |
Enanta Pharmacueticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
EP3911647B1
(en)
|
2019-01-15 |
2023-12-13 |
Gilead Sciences, Inc. |
Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
|
|
PL3923943T3
(pl)
|
2019-02-12 |
2024-12-09 |
Mirum Pharmaceuticals, Inc. |
Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
|
|
AU2020221371A1
(en)
|
2019-02-15 |
2021-10-07 |
Bristol-Myers Squibb Company |
Substituted amide compounds useful as farnesoid x receptor modulators
|
|
CN113727973B
(zh)
|
2019-02-15 |
2025-08-29 |
百时美施贵宝公司 |
可用作类法尼醇x受体调节剂的取代酰胺化合物
|
|
JP7465883B2
(ja)
|
2019-02-15 |
2024-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
|
|
AR118050A1
(es)
|
2019-02-15 |
2021-09-15 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
|
|
CA3233305A1
(en)
|
2019-02-19 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
KR20220035365A
(ko)
|
2019-07-18 |
2022-03-22 |
엔요 파마 |
인터페론의 부작용을 감소시키는 방법
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
JP2024502673A
(ja)
|
2021-01-14 |
2024-01-22 |
ウエヌイグレックオ・ファーマ |
Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
|
|
JP2024517181A
(ja)
|
2021-04-28 |
2024-04-19 |
ウエヌイグレックオ・ファーマ |
組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
|